Literature DB >> 21766055

Combined approach to counteract experimental cancer cachexia: eicosapentaenoic acid and training exercise.

Fabio Penna, Silvia Busquets, Fabrizio Pin, Miriam Toledo, Francesco M Baccino, Francisco J López-Soriano, Paola Costelli, Josep M Argilés.   

Abstract

BACKGROUND: Cancer cachexia is a syndrome characterized by loss of skeletal muscle protein, depletion of lipid stores, anorexia, weakness, and perturbations of the hormonal homeostasis. Despite several therapeutic approaches described in the past, effective interventions countering cancer cachexia are still lacking.
METHODS: The present work was aimed to verify the ability of eicosapentaenoic acid (EPA) to prevent the muscle depletion in Lewis lung carcinoma-bearing mice and to test the ability of endurance exercise training to increase the EPA effect.
RESULTS: EPA alone did not prevent the muscle loss induced by tumor growth while the combination with exercise induced a partial rescue of muscle strength and mass. Moreover, the association of EPA and exercise reduced the dramatic PAX-7 accumulation and stimulated the increase of PCG-1 protein.
CONCLUSIONS: Overall, the present data suggest that exercise is an effective tool that should be added for combined therapeutic approaches against cancer cachexia. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s13539-011-0028-4) contains supplementary material, which is available to authorized users.

Entities:  

Year:  2011        PMID: 21766055      PMCID: PMC3118004          DOI: 10.1007/s13539-011-0028-4

Source DB:  PubMed          Journal:  J Cachexia Sarcopenia Muscle        ISSN: 2190-5991            Impact factor:   12.910


  42 in total

1.  Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.

Authors:  M D Gomes; S H Lecker; R T Jagoe; A Navon; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Effect of eicosapentaenoic acid (EPA) on expression of a lipid mobilizing factor in adipose tissue in cancer cachexia.

Authors:  S T Russell; M J Tisdale
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2005-06       Impact factor: 4.006

3.  Double-blind, placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia.

Authors:  Kenneth C H Fearon; Matthew D Barber; Alastair G Moses; Sam H Ahmedzai; Gillian S Taylor; Michael J Tisdale; Gordon D Murray
Journal:  J Clin Oncol       Date:  2006-07-20       Impact factor: 44.544

4.  Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial.

Authors:  K C H Fearon; M F Von Meyenfeldt; A G W Moses; R Van Geenen; A Roy; D J Gouma; A Giacosa; A Van Gossum; J Bauer; M D Barber; N K Aaronson; A C Voss; M J Tisdale
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

5.  Effects of high-intensity resistance training in patients with rheumatoid arthritis: a randomized controlled trial.

Authors:  Andrew B Lemmey; Samuele M Marcora; Kathryn Chester; Sally Wilson; Francesco Casanova; Peter J Maddison
Journal:  Arthritis Rheum       Date:  2009-12-15

Review 6.  Therapeutic potential of n-3 polyunsaturated fatty acids in disease.

Authors:  James W Fetterman; Martin M Zdanowicz
Journal:  Am J Health Syst Pharm       Date:  2009-07-01       Impact factor: 2.637

Review 7.  Management of cancer-related fatigue.

Authors:  Andrea M Barsevick; Tracey Newhall; Susan Brown
Journal:  Clin J Oncol Nurs       Date:  2008-10       Impact factor: 1.027

8.  Effect of endurance training upon lipid metabolism in the liver of cachectic tumour-bearing rats.

Authors:  F S Lira; F L Tavares; A S Yamashita; C H Koyama; M J Alves; E C Caperuto; M L Batista; M Seelaender
Journal:  Cell Biochem Funct       Date:  2008-08       Impact factor: 3.685

9.  Anti-interferon-gamma antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexia.

Authors:  P Matthys; H Heremans; G Opdenakker; A Billiau
Journal:  Eur J Cancer       Date:  1991       Impact factor: 9.162

Review 10.  Cyclooxygenase-2 inhibitors and antioxidants in the treatment of cachexia.

Authors:  Giovanni Mantovani; Clelia Madeddu
Journal:  Curr Opin Support Palliat Care       Date:  2008-12       Impact factor: 2.302

View more
  34 in total

Review 1.  The emerging role of skeletal muscle oxidative metabolism as a biological target and cellular regulator of cancer-induced muscle wasting.

Authors:  James A Carson; Justin P Hardee; Brandon N VanderVeen
Journal:  Semin Cell Dev Biol       Date:  2015-12-01       Impact factor: 7.727

2.  What Can be Learned from the Time Course of Changes in Low-Frequency Stimulated Muscle?

Authors:  Dirk Pette
Journal:  Eur J Transl Myol       Date:  2017-06-24

3.  Abstracts of the 2(nd) Cancer Cachexia Conference, Montreal, Canada, 26-28 September 2014.

Authors: 
Journal:  J Cachexia Sarcopenia Muscle       Date:  2015-03-31       Impact factor: 12.910

4.  Nuclear to cytoplasmic shuttling of ERK promotes differentiation of muscle stem/progenitor cells.

Authors:  Inbal Michailovici; Heather A Harrington; Hadar Hay Azogui; Yfat Yahalom-Ronen; Alexander Plotnikov; Saunders Ching; Michael P H Stumpf; Ophir D Klein; Rony Seger; Eldad Tzahor
Journal:  Development       Date:  2014-06-12       Impact factor: 6.868

5.  Eccentric contraction-induced myofiber growth in tumor-bearing mice.

Authors:  Justin P Hardee; Joshua E Mangum; Song Gao; Shuichi Sato; Kimbell L Hetzler; Melissa J Puppa; Dennis K Fix; James A Carson
Journal:  J Appl Physiol (1985)       Date:  2015-10-22

Review 6.  Sarcopenia versus cancer cachexia: the muscle wasting continuum in healthy and diseased aging.

Authors:  Alexandra Moreira-Pais; Rita Ferreira; Paula A Oliveira; José A Duarte
Journal:  Biogerontology       Date:  2021-07-29       Impact factor: 4.277

7.  Selecting for predisposition to cancer cachexia.

Authors:  Ioannis Gioulbasanis; Panagiotis J Vlachostergios; Christos N Papandreou
Journal:  EMBO Mol Med       Date:  2012-04-11       Impact factor: 12.137

8.  Molecular and cellular mechanisms of skeletal muscle atrophy: an update.

Authors:  Alessandro Fanzani; Viviane M Conraads; Fabio Penna; Wim Martinet
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-06-07       Impact factor: 12.910

9.  Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia.

Authors:  Vanessa C Vaughan; Melanie Sullivan-Gunn; Edward Hinch; Peter Martin; Paul A Lewandowski
Journal:  PLoS One       Date:  2012-09-20       Impact factor: 3.240

10.  Cancer cachexia: impact, mechanisms and emerging treatments.

Authors:  Vanessa C Vaughan; Peter Martin; Paul A Lewandowski
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-10-25       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.